Patents by Inventor Shane McCarthy

Shane McCarthy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1
    Patent number: 12612462
    Abstract: IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.
    Type: Grant
    Filed: June 7, 2023
    Date of Patent: April 28, 2026
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shannon Bruse, Shane McCarthy, Aris Baras, Frederick Dewey, Omri Gottesman
  • Treatment And Inhibition Of Inflammatory Lung Diseases In Patients Having Risk Alleles In The Genes Encoding IL33 And IL1RL1
    Publication number: 20230374145
    Abstract: IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.
    Type: Application
    Filed: June 7, 2023
    Publication date: November 23, 2023
    Inventors: Shannon Bruse, Shane McCarthy, Aris Baras, Frederick Dewey, Omri Gottesman
  • Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1
    Patent number: 11708415
    Abstract: IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: July 25, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shannon Bruse, Shane McCarthy, Aris Baras, Frederick Dewey, Omri Gottesman
  • Treatment And Inhibition Of Inflammatory Lung Diseases In Patients Having Risk Alleles In The Genes Encoding IL33 And IL1RL1
    Publication number: 20200031922
    Abstract: IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.
    Type: Application
    Filed: October 11, 2019
    Publication date: January 30, 2020
    Inventors: Shannon BRUSE, Shane McCARTHY, Aris BARAS, Frederick DEWEY, Omri GOTTESMAN
  • Compositions And Methods For The Diagnosis of Schizophrenia
    Publication number: 20140171371
    Abstract: The present disclosure relates to compositions and methods for the diagnosis of schizophrenia. In particular, the instant disclosure is directed to identification of novel copy number variants of sequences associated with the VIPR2 gene, including certain micro-duplications and triplications, and correlation of these copy number variants with schizophrenia.
    Type: Application
    Filed: July 3, 2013
    Publication date: June 19, 2014
    Inventors: Vladimir Vacic, Shane McCarthy, Dheeraj Malhotra, Fiona Murray, Hsun-Hua Chou, Veronica Larach-Walters, Paul A. Insel, Maria Karayiorgou, Lynn E. DeLisi, Jonathan Sebat